SG Americas Securities LLC boosted its stake in bluebird bio, Inc. (NASDAQ:BLUE) by 104.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,982 shares of the biotechnology company’s stock after buying an additional 2,037 shares during the quarter. SG Americas Securities LLC’s holdings in bluebird bio were worth $547,000 at the end of the most recent reporting period.
A number of other institutional investors also recently modified their holdings of BLUE. QS Investors LLC increased its holdings in shares of bluebird bio by 70.7% during the 2nd quarter. QS Investors LLC now owns 1,207 shares of the biotechnology company’s stock worth $127,000 after buying an additional 500 shares during the last quarter. World Asset Management Inc acquired a new stake in shares of bluebird bio during the 3rd quarter worth approximately $230,000. Bank of Montreal Can increased its holdings in shares of bluebird bio by 118.9% during the 2nd quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock worth $176,000 after buying an additional 911 shares during the last quarter. Comerica Bank acquired a new stake in shares of bluebird bio during the 3rd quarter worth approximately $242,000. Finally, Turner Investments LLC acquired a new stake in shares of bluebird bio during the 2nd quarter worth approximately $184,000.
In other bluebird bio news, insider Jeffrey T. Walsh sold 4,900 shares of the company’s stock in a transaction dated Tuesday, October 10th. The shares were sold at an average price of $129.94, for a total transaction of $636,706.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Nick Leschly sold 10,823 shares of the company’s stock in a transaction dated Tuesday, October 17th. The stock was sold at an average price of $145.05, for a total transaction of $1,569,876.15. Following the transaction, the chief executive officer now owns 262,409 shares in the company, valued at $38,062,425.45. The disclosure for this sale can be found here. Insiders have sold 211,082 shares of company stock worth $36,702,092 over the last 90 days. 3.90% of the stock is currently owned by company insiders.
Several analysts recently weighed in on BLUE shares. Wells Fargo & Co reiterated an “outperform” rating and issued a $158.00 target price (up previously from $134.00) on shares of bluebird bio in a report on Tuesday, September 5th. Barclays began coverage on shares of bluebird bio in a report on Wednesday, September 6th. They issued an “overweight” rating and a $151.00 target price for the company. Cantor Fitzgerald restated a “sell” rating and issued a $39.00 price target on shares of bluebird bio in a research note on Thursday, September 28th. Leerink Swann restated an “outperform” rating and issued a $120.00 price target on shares of bluebird bio in a research note on Saturday, September 30th. Finally, Morgan Stanley downgraded shares of bluebird bio from an “equal weight” rating to an “underweight” rating and set a $105.00 price target for the company. in a research note on Monday, October 2nd. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and thirteen have issued a buy rating to the stock. bluebird bio currently has an average rating of “Hold” and a consensus price target of $157.45.
Shares of bluebird bio, Inc. (BLUE) traded up $3.80 during trading on Tuesday, hitting $181.90. 494,650 shares of the stock were exchanged, compared to its average volume of 999,721. bluebird bio, Inc. has a twelve month low of $60.95 and a twelve month high of $222.03. The firm has a market capitalization of $8,340.00, a price-to-earnings ratio of -25.95 and a beta of 2.08.
bluebird bio (NASDAQ:BLUE) last issued its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.68) by ($0.05). bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. The firm had revenue of $7.71 million for the quarter, compared to analyst estimates of $8.47 million. During the same quarter last year, the firm earned ($2.07) earnings per share. The company’s revenue was up 397.4% compared to the same quarter last year. analysts expect that bluebird bio, Inc. will post -6.72 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “bluebird bio, Inc. (BLUE) Position Boosted by SG Americas Securities LLC” was reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://www.truebluetribune.com/2018/01/03/sg-americas-securities-llc-boosts-holdings-in-bluebird-bio-inc-blue.html.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.